Chronic Obstructive Pulmonary DiseaseCORSAINCT04628962
Raman Analysis of Saliva as Biomarker of COPD
An observational study of Chronic Obstructive Pulmonary Disease, run by Fondazione Don Carlo Gnocchi ETS at 5 sites in 4 countries.
Trial summary
Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and chronic lung syndrome that causes accelerated lung function decline and death in the 20% of cases. Mostly, the non-adherence to therapy contributes to symptoms increase, mortality, inability and therapies failure, highly influencing the management… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease
- What is being tested?
- Collection and Raman analysis of saliva for the database
- Type of treatment
- Surgery or procedure
- How many people
- 250 participants
- Where
- 5 sitesin 4 countries
- Study dates
- 1 Feb 2022to 1 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will be recruited from the primary care clinic patients under treatment at IRCCS Fondazione Don Carlo Gnocchi ONLUS - Ospedale Santa Maria Nascente, Milano (Italy); Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, (Spain); Riga Stradins University (RSU), Riga (Latvia)
Who may be able to join
- COPD patients will be defined as a postbronchodilator ratio of FEV1/FEV <0.7. The severity of airflow limitation and phenotypes will be defined as described by the GOLD grading system, including Grade 2, 3 or 4.
- Overlapped Asthma - COPD will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
- Sex and age matched HC and AsP (bronchial asthma according to The Global Strategy for Asthma Management and Prevention 2018 from at least 6 months) will be recruited as controls.
Who cannot join
- Exclusion criteria will be the combination with obstructive sleep apnea, cancer, MMSE<24, at least 4 weeks from the last acute exacerbation, cardiovascular, neurologic and kidney diseases, age<18
- Bacterial or fungal oral infections in progress
Trial locations and contacts
5 sites in 4 countries.
5 sites in 4 countries
Italy2 sites, 1 recruiting
- Recruiting
IRCCS Santa Maria Nascente - Fondazione Don Carlo Gnocchi ONLUS
Milan, 20148
Paolo I Banfi, MD, 02 40308812 ext. +39, pabanfi@dongnocchi.it
Marzia Bedoni, PhD, 0240308533 ext. +39, labion@dongnocchi.it
- Active, not recruiting
University of Milano-Bicocca
Milan
Germany1 site
- Active, not recruiting
Geratherm Respiratory GmbH
Bad Kissingen, 97688
Latvia1 site, 1 recruiting
- Recruiting
Riga Stradins University
Riga, LV1007
Madara Tirzīte, MD, 167409105 ext. +37, madara.tirzite@rsu.lv
Spain1 site, 1 recruiting
- Recruiting
Institut d'Investigacions Biomèdiques August Pi I Sunyer
Barcelona, 08036
Nestor Soler, MD, 2275549 ext. +34, nsoler@clinic.cat
About this study
Official title: Raman Analysis of Saliva From COPD Patients as New Biomarker: AI-based Point-of-care for the Disease Monitoring and Management
Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and chronic lung syndrome that causes accelerated lung function decline and death in the 20% of cases. Mostly, the non-adherence to therapy contributes to symptoms increase, mortality, inability and therapies failure, highly influencing the management costs associated to COPD. The existing procedure of diagnosing COPD is effective and fast. The acute treatment and the subsequent disease management, instead, strictly depend on the currently long and complex process of identification of three factors: COPD phenotype, adherence to chosen therapy and probability of exacerbation events. The knowledge of these factors is needed by clinicians to stratify patients and personalise the therapies and rehabilitation procedures, to initiate an effective disease management. The application of Raman spectroscopy on saliva, representing an easy collectable and highly informative biofluid, has been already proposed for different infective, neurological and cancer diseases, with promising results in the diagnostic and monitoring fields. In this project, we propose the use of Deep Learning analysis of Raman spectra collected from COPD patient's saliva to be combined with other clinical data for the development of a system able to provide fast and sensitive information regarding COPD phenotypes, adherence and exacerbation risks. This will support clinicians to personalise COPD therapies and treatments, and to monitor their effectiveness.
Read the detailed description
The main goal of the project is to create and validate a new method based on the Raman spectroscopy (RS) analysis of saliva for the optimised and personalised management of patients with Chronic Obstructive Pulmonary disease (COPD). The combination of the clinical instrumental data with the RS-approach will increase the quality of the clinical practice through appropriate stratification of patients, i.e., early identification of COPD phenotypes, consequent attribution of precise therapies, assessment of potential exacerbation risk and adherence to therapy. By the integration of instrumental and RS measures with Artificial Intelligence (AI), patients' COPD phenotype will be predicted allowing to efficiently direct the resources of the health-care system. The feasibility of the work is corroborated by the use of a sensitive, fast and miniaturized RS, used by non-specialized personnel and for the creation of a point-of care (POC) on an accessible biofluid. The multidisciplinary approach in pre-clinical, clinical and big data management fields is achieved through collaboration of academy, clinical research and industry.
Starting from the unmet clinical need, CORSAI will build a close link between biomedical research, clinical research, data science towards the integration of PM into clinical practice and on ethical, legal, and social implications across the participating countries and beyond. The main objective is the collection of RS signals from the saliva of COPD patients, characterized for severity stages and phenotypes using GERA instruments, and corresponding CTRL and asthma patients (AsP). The creation and correlation of the dataset will lead to the accomplishment of specific objectives: I) Identification of the specific COPD, CTRL and AsP RF; II) Monitoring of therapy adherence through the drug signal in saliva; III) Definition of COPD phenotypes on the base of the RF correlated with instrumental GERA data; IV) Monitoring of the rehabilitation procedures and effects; V) Association of a high exacerbation risk to specific COPD patients; VI) Creation of a classification model from the RS database; VII) Application of high-performance computing for data analysis; VIII) Integration of the portable RS as POC. The novelty of CORSAI relies in the advanced methodology, brought to the bed side thanks to portable instruments. The minimal invasive procedure used for the saliva collection and the velocity for the Raman acquisition represent relevant advantages allowing the continuous monitoring of patients' adherence to therapy, and the contemporary discrimination of COPD phenotypes with high rate of exacerbation. The feasibility of the project is directly related to the biological sample and proposed technology, already tested in the clinical setting19: i)easy collection and storage of saliva fits the clinical scenario; ii) minimal sample preparation and portable device enable POC use by non-specialized personnel, with AI remote decision guidance.
SAMPLE COLLECTION: Saliva collection from all the selected subjects will be performed following the Salivette (SARSTEDT) manufacturer's instructions. To limit variability in salivary content not related to COPD, saliva will be obtained from all subjects at a fixed time, after an appropriate lag time from feeding and teeth brushing. Pre-analytical parameters (i.e. storage temperature and time between collection and processing), dietary and smoking habit will be properly recorded. Briefly, the swab will be removed, placed in the mouth and chewed for 60 seconds to stimulate salivation. Then the swab will be centrifuged for 2 minutes at 1,000 g to remove cells fragments and food debris. Collected samples will be stored at -80° C.
SAMPLE PROCESSING: For the Raman analysis, a drop of each sample will be casted on an aluminium foil in order to achieve the Surface Enhanced Raman Scattering (SERS).
DATA COLLECTION: SERS spectra will be acquired using an Aramis Raman microscope (Horiba Jobin-Yvon, France) equipped with a laser light source operating at 785 nm with laser power ranging from 25-100% (Max power 512 mW). Acquisition time between 10-30 seconds will be used. The instrument will be calibrated before each analysis using the reference band of silicon at 520.7 cm-1. Raman spectra will be collected from 35 points following a line-map from the edge to the centre of the drop. Spectra will be acquired in the region between 400 and 1600 cm-1 using a 50x objective (Olympus, Japan). Spectra resolution is about 1.2 cm-1. The software package LabSpec 6 (Horiba Jobin-Yvon, France) will be used for map design and the acquisition of spectra.
DATA PROCESSING: All the acquired spectra will be fit with a fourth-degree polynomial baseline and normalized by unit vector using the dedicated software LabSpec 6. The contribution of the substrate will be removed from each spectra. The statistical analysis to validate the method, will be performed using a multivariate analysis approach. Principal Component analysis (PCA) will be performed in order to reduce data dimensions and to evidence major trends. The first 20 resultant Principal Components (PCs) will be used in a classification model, Linear Discriminant Analysis (LDA), to discriminate the data maximizing the variance between the selected groups. The smallest number of PCs will be selected to prevent data overfitting. Leave-one-out cross-validation and confusion matrix test will be used to evaluate the method sensitivity, precision and accuracy of the LDA model. Mann-Whitney will be performed on PCs scores to verify the differences statistically relevant between the analysed groups. Correlation and partial correlation analysis will be performed using the Spearman's test, assuming as valid correlation only the coefficients with a p-value lower than 0.05. The statistical analysis will be performed using Origin2018 (OriginLab, USA).
DEEP LEARNING: The datasets will be analysed and processed using Deep Learning models with the aim to discover significant patterns that can be used to confirm and analyse trends and to develop predictions and decision support about the COPD stratification. Techniques of data augmentation and automatic hyperparameter optimization will be developed in order to enhance classification performances and improve generalization ability. In order to reach a tradeoff between predictive accuracy and interpretability, a class activation mapping (CAM)-based approach will be applied to visualize the active variables in the spectra in order to identify discriminative pattern to extract the most informative spectral features.
UNIMIB and GERA will implement an explanation mechanism to identify the active variables in whole spectrum and interpret the internal feature representations and data transformation pipeline of the CNN model. UNIMIB and GERA will integrate the various computational modules in a modular computational pipeline for patient-wise classification.
- Conditions
- Chronic Obstructive Pulmonary Disease
- Being tested
- Collection and Raman analysis of saliva for the database
- Keywords
- Raman Spectroscopy, COPD, Machine Learning, Biomarker
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection and Raman analysis of saliva for the databaseProcedure or surgery
Saliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model
| Study group | Role | What they receive |
|---|---|---|
| Asthma-COPD Overlapped (aCOPD) | 50 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO Receives: Procedure: Collection and Raman analysis of saliva for the database | |
| Non-Exacerbator COPD (neCOPD) | 50 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects Receives: Procedure: Collection and Raman analysis of saliva for the database | |
| frequent Excacerbator with Emphysema COPD (eeCOPD) | 50 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects Receives: Procedure: Collection and Raman analysis of saliva for the database | |
| frequent Excacerbator with chronic Bronchitis COPD (ebCOPD) | 50 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects Receives: Procedure: Collection and Raman analysis of saliva for the database | |
| Asthma patients (AST) | 200 subjects affected by asthma comparable by age and sex with the other recruited subjects Receives: Procedure: Collection and Raman analysis of saliva for the database | |
| Healthy subjects (CTRL) | 200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects Receives: Procedure: Collection and Raman analysis of saliva for the database |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identification of the salivary COPD Raman signature
Raman spectroscopy will be used to analyse saliva of COPD patients, leading to the characterization of a specific COPD signature highlighting the differences between the one of asthma patients and healthy subjects. Using multivariate analysis, the possibility to create a classification model will be tested.
Measured: Two years
Characterization of the spectral differences of COPD patients
Raman data will be interpreted comparing the signatures of the different experimental groups (COPD vs asthma vs healthy subjects), identifing the molecular classes responsible for the principal differences
Measured: Two years
Stratification of the 4 COPD phenotypes through the Raman signature
An intra COPD class analysis will be performed, identifying the specific Raman signature of each phenotype considered in the study. The multivariate analysis will be performed evaluating the possibility to create a classification model able to perform a fast diagnosis based on the analysis of saliva
Measured: Two years
Monitoring of therapy adherence and effects
Raman data will be correlated with the clinical parameters, identifying hidden trends and relationships between the two investigated factors. In particular, the effects of a full and missing therapy adherence will be evaluated in terms of changing in salivary Raman signatures
Measured: Two years
Determination of the exacerbation index
The Raman signal associated with frequently exacerbator patients will be computed through linear discriminant analysis, obtaing coefficients related to the exacerbation event. In this way, a measurable parameter will be created in order to monitor and potentially forecast the exacerbation events
Measured: Two years
Application of a portable Raman spectrometer as Point of Care
All the data, databases and classification models created in the previous outcomes will be integrated in a portable Raman instrument that will be applied directly on new patinets, in order to test the reliability of the methodology. At the same time, the new data will be used to train the model, increasing the discriminatory power in terms of accuracy, precision, sensitivity and specificity
Measured: Three years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Nov 2020
- Study start1 Feb 2022
- Primary completion30 Nov 2023 (estimated)
- Study completion1 Jan 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Chronic Obstructive Pulmonary DiseaseStudies of the same condition, open and under way.
- More trials run by Fondazione Don Carlo Gnocchi ETSThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fondazione Don Carlo Gnocchi ETS
- Sponsor type
- University, hospital or other
- Collaborators
- Geratherm Respiratory GmbH, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Riga Stradins University, University of Milano Bicocca
- Responsible party
- Sponsor
- Investigators
- Marzia Bedoni, PhD, Study chair, Fondazione Don Carlo Gnocchi ONLUS, Laboratory of Nanomedicine and Clinical BiophotonicsPaolo I Banfo, MD, Principal investigator, Fondazione Don Carlo Gnocchi ETS
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04628962
- Sponsor's protocol ID
- FDG_RamanSaliva_COPD_CORSAI
- Other IDs
- ERAPERMED2021-383_CORSAI
- Acronym
- CORSAI
- Status last verified
- Feb 2022
- First submitted
- 9 Nov 2020
- Last updated
- 4 Apr 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Carlomagno C, Banfi PI, Gualerzi A, Picciolini S, Volpato E, Meloni M, Lax A, Colombo E, Ticozzi N, Verde F, Silani V, Bedoni M. Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis. Sci Rep. 2020 Jun 23;10(1):10175. doi: 10.1038/s41598-020-67138-8.
PubMed 32576912Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. 2018 Oct;93(10):1488-1502. doi: 10.1016/j.mayocp.2018.05.026.
PubMed 30286833Nikolaou V, Massaro S, Fakhimi M, Stergioulas L, Price D. COPD phenotypes and machine learning cluster analysis: A systematic review and future research agenda. Respir Med. 2020 Sep;171:106093. doi: 10.1016/j.rmed.2020.106093. Epub 2020 Jul 28.
PubMed 32745966Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012 Mar;48(3):86-98. doi: 10.1016/j.arbres.2011.10.007. Epub 2011 Dec 22. English, Spanish.
PubMed 22196477
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Raman Analysis of Saliva From COPD Patients as New Biomarker: AI-based Point-of-care for the Disease Monitoring and Management
- ClinicalTrials.gov ID
- NCT04628962
- Acronym / sponsor ID
- CORSAI / FDG_RamanSaliva_COPD_CORSAI
- Conditions
- Chronic Obstructive Pulmonary Disease
- Keywords
- Raman Spectroscopy, COPD, Machine Learning, Biomarker
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Fondazione Don Carlo Gnocchi ETSUniversity, hospital or other
- Collaborators
- Geratherm Respiratory GmbH, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Riga Stradins University, University of Milano Bicocca
- Study start
- 1 Feb 2022 (actual)
- Primary completion
- 30 Nov 2023 (estimated)
- Study completion
- 1 Jan 2025 (estimated)
- First posted
- 16 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and chronic lung syndrome that causes accelerated lung function decline and death in the 20% of cases. Mostly, the non-adherence to therapy contributes to symptoms increase, mortality, inability and therapies failure, highly influencing the management costs associated to COPD. The existing procedure of diagnosing COPD is effective and fast. The acute treatment and the subsequent disease management, instead, strictly depend on the currently long and complex process of identification of three factors: COPD phenotype, adherence to chosen therapy and probability of exacerbation events. The knowledge of these factors is needed by clinicians to stratify patients and personalise the therapies and rehabilitation procedures, to initiate an effective disease management. The application of Raman spectroscopy on saliva, representing an easy collectable and highly informative biofluid, has been already proposed for different infective, neurological and cancer diseases, with promising results in the diagnostic and monitoring fields. In this project, we propose the use of Deep Learning analysis of Raman spectra collected from COPD patient's saliva to be combined with other clinical data for the development of a system able to provide fast and sensitive information regarding COPD phenotypes, adherence and exacerbation risks. This will support clinicians to personalise COPD therapies and treatments, and to monitor their effectiveness.
Detailed description
The main goal of the project is to create and validate a new method based on the Raman spectroscopy (RS) analysis of saliva for the optimised and personalised management of patients with Chronic Obstructive Pulmonary disease (COPD). The combination of the clinical instrumental data with the RS-approach will increase the quality of the clinical practice through appropriate stratification of patients, i.e., early identification of COPD phenotypes, consequent attribution of precise therapies, assessment of potential exacerbation risk and adherence to therapy. By the integration of instrumental and RS measures with Artificial Intelligence (AI), patients' COPD phenotype will be predicted allowing to efficiently direct the resources of the health-care system. The feasibility of the work is corroborated by the use of a sensitive, fast and miniaturized RS, used by non-specialized personnel and for the creation of a point-of care (POC) on an accessible biofluid. The multidisciplinary approach in pre-clinical, clinical and big data management fields is achieved through collaboration of academy, clinical research and industry.
Starting from the unmet clinical need, CORSAI will build a close link between biomedical research, clinical research, data science towards the integration of PM into clinical practice and on ethical, legal, and social implications across the participating countries and beyond. The main objective is the collection of RS signals from the saliva of COPD patients, characterized for severity stages and phenotypes using GERA instruments, and corresponding CTRL and asthma patients (AsP). The creation and correlation of the dataset will lead to the accomplishment of specific objectives: I) Identification of the specific COPD, CTRL and AsP RF; II) Monitoring of therapy adherence through the drug signal in saliva; III) Definition of COPD phenotypes on the base of the RF correlated with instrumental GERA data; IV) Monitoring of the rehabilitation procedures and effects; V) Association of a high exacerbation risk to specific COPD patients; VI) Creation of a classification model from the RS database; VII) Application of high-performance computing for data analysis; VIII) Integration of the portable RS as POC. The novelty of CORSAI relies in the advanced methodology, brought to the bed side thanks to portable instruments. The minimal invasive procedure used for the saliva collection and the velocity for the Raman acquisition represent relevant advantages allowing the continuous monitoring of patients' adherence to therapy, and the contemporary discrimination of COPD phenotypes with high rate of exacerbation. The feasibility of the project is directly related to the biological sample and proposed technology, already tested in the clinical setting19: i)easy collection and storage of saliva fits the clinical scenario; ii) minimal sample preparation and portable device enable POC use by non-specialized personnel, with AI remote decision guidance.
SAMPLE COLLECTION: Saliva collection from all the selected subjects will be performed following the Salivette (SARSTEDT) manufacturer's instructions. To limit variability in salivary content not related to COPD, saliva will be obtained from all subjects at a fixed time, after an appropriate lag time from feeding and teeth brushing. Pre-analytical parameters (i.e. storage temperature and time between collection and processing), dietary and smoking habit will be properly recorded. Briefly, the swab will be removed, placed in the mouth and chewed for 60 seconds to stimulate salivation. Then the swab will be centrifuged for 2 minutes at 1,000 g to remove cells fragments and food debris. Collected samples will be stored at -80° C.
SAMPLE PROCESSING: For the Raman analysis, a drop of each sample will be casted on an aluminium foil in order to achieve the Surface Enhanced Raman Scattering (SERS).
DATA COLLECTION: SERS spectra will be acquired using an Aramis Raman microscope (Horiba Jobin-Yvon, France) equipped with a laser light source operating at 785 nm with laser power ranging from 25-100% (Max power 512 mW). Acquisition time between 10-30 seconds will be used. The instrument will be calibrated before each analysis using the reference band of silicon at 520.7 cm-1. Raman spectra will be collected from 35 points following a line-map from the edge to the centre of the drop. Spectra will be acquired in the region between 400 and 1600 cm-1 using a 50x objective (Olympus, Japan). Spectra resolution is about 1.2 cm-1. The software package LabSpec 6 (Horiba Jobin-Yvon, France) will be used for map design and the acquisition of spectra.
DATA PROCESSING: All the acquired spectra will be fit with a fourth-degree polynomial baseline and normalized by unit vector using the dedicated software LabSpec 6. The contribution of the substrate will be removed from each spectra. The statistical analysis to validate the method, will be performed using a multivariate analysis approach. Principal Component analysis (PCA) will be performed in order to reduce data dimensions and to evidence major trends. The first 20 resultant Principal Components (PCs) will be used in a classification model, Linear Discriminant Analysis (LDA), to discriminate the data maximizing the variance between the selected groups. The smallest number of PCs will be selected to prevent data overfitting. Leave-one-out cross-validation and confusion matrix test will be used to evaluate the method sensitivity, precision and accuracy of the LDA model. Mann-Whitney will be performed on PCs scores to verify the differences statistically relevant between the analysed groups. Correlation and partial correlation analysis will be performed using the Spearman's test, assuming as valid correlation only the coefficients with a p-value lower than 0.05. The statistical analysis will be performed using Origin2018 (OriginLab, USA).
DEEP LEARNING: The datasets will be analysed and processed using Deep Learning models with the aim to discover significant patterns that can be used to confirm and analyse trends and to develop predictions and decision support about the COPD stratification. Techniques of data augmentation and automatic hyperparameter optimization will be developed in order to enhance classification performances and improve generalization ability. In order to reach a tradeoff between predictive accuracy and interpretability, a class activation mapping (CAM)-based approach will be applied to visualize the active variables in the spectra in order to identify discriminative pattern to extract the most informative spectral features.
UNIMIB and GERA will implement an explanation mechanism to identify the active variables in whole spectrum and interpret the internal feature representations and data transformation pipeline of the CNN model. UNIMIB and GERA will integrate the various computational modules in a modular computational pipeline for patient-wise classification.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Asthma-COPD Overlapped (aCOPD) | – | Procedure: Collection and Raman analysis of saliva for the database50 subjects affected by Asthma-COPD Overlapped comparable by age and sex with the other recruited subjects. The diagnosis of the mixed phenotypes will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO |
| Non-Exacerbator COPD (neCOPD) | – | Procedure: Collection and Raman analysis of saliva for the database50 subjects affected by Non-Exacerbator COPD comparable by age and sex with the other recruited subjects |
| frequent Excacerbator with Emphysema COPD (eeCOPD) | – | Procedure: Collection and Raman analysis of saliva for the database50 subjects affected by frequent exacerbation with emphysema COPD comparable by age and sex with the other recruited subjects |
| frequent Excacerbator with chronic Bronchitis COPD (ebCOPD) | – | Procedure: Collection and Raman analysis of saliva for the database50 subjects affected by frequent excacerbation with chronic bronchitis COPD comparable by age and sex with the other recruited subjects |
| Asthma patients (AST) | – | Procedure: Collection and Raman analysis of saliva for the database200 subjects affected by asthma comparable by age and sex with the other recruited subjects |
| Healthy subjects (CTRL) | – | Procedure: Collection and Raman analysis of saliva for the database200 healthy subjects in a good health state comparable by age and sex with the other recruited subjects |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will be recruited from the primary care clinic patients under treatment at IRCCS Fondazione Don Carlo Gnocchi ONLUS - Ospedale Santa Maria Nascente, Milano (Italy); Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, (Spain); Riga Stradins University (RSU), Riga (Latvia)
Key inclusion criteria (3 listed)
- COPD patients will be defined as a postbronchodilator ratio of FEV1/FEV <0.7. The severity of airflow limitation and phenotypes will be defined as described by the GOLD grading system, including Grade 2, 3 or 4.
- Overlapped Asthma - COPD will be established by the presence of a combination of the following factors: history of asthma and/or atopy, reversibility in the bronchodilator test, notable eosinophilia in respiratory and/or peripheral secretions, high IgE, positive prick test to pneumoallergens and high concentrations of exhaled NO
- Sex and age matched HC and AsP (bronchial asthma according to The Global Strategy for Asthma Management and Prevention 2018 from at least 6 months) will be recruited as controls.
Key exclusion criteria (2 listed)
- Exclusion criteria will be the combination with obstructive sleep apnea, cancer, MMSE<24, at least 4 weeks from the last acute exacerbation, cardiovascular, neurologic and kidney diseases, age<18
- Bacterial or fungal oral infections in progress
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection and Raman analysis of saliva for the databaseSaliva will be collected and processed for the Raman analysis. The collected data will be computed for the creation of the classification model | Procedure or surgery | Asthma patients (AST), Asthma-COPD Overlapped (aCOPD), Healthy subjects (CTRL), Non-Exacerbator COPD (neCOPD), frequent Excacerbator with Emphysema COPD (eeCOPD), frequent Excacerbator with chronic Bronchitis COPD (ebCOPD) |
Primary outcome
Identification of the salivary COPD Raman signature
Time frame: Two years
Raman spectroscopy will be used to analyse saliva of COPD patients, leading to the characterization of a specific COPD signature highlighting the differences between the one of asthma patients and healthy subjects. Using multivariate analysis, the possibility to create a classification model will be tested.
Characterization of the spectral differences of COPD patients
Time frame: Two years
Raman data will be interpreted comparing the signatures of the different experimental groups (COPD vs asthma vs healthy subjects), identifing the molecular classes responsible for the principal differences
Stratification of the 4 COPD phenotypes through the Raman signature
Time frame: Two years
An intra COPD class analysis will be performed, identifying the specific Raman signature of each phenotype considered in the study. The multivariate analysis will be performed evaluating the possibility to create a classification model able to perform a fast diagnosis based on the analysis of saliva
Monitoring of therapy adherence and effects
Time frame: Two years
Raman data will be correlated with the clinical parameters, identifying hidden trends and relationships between the two investigated factors. In particular, the effects of a full and missing therapy adherence will be evaluated in terms of changing in salivary Raman signatures
Determination of the exacerbation index
Time frame: Two years
The Raman signal associated with frequently exacerbator patients will be computed through linear discriminant analysis, obtaing coefficients related to the exacerbation event. In this way, a measurable parameter will be created in order to monitor and potentially forecast the exacerbation events
Application of a portable Raman spectrometer as Point of Care
Time frame: Three years
All the data, databases and classification models created in the previous outcomes will be integrated in a portable Raman instrument that will be applied directly on new patinets, in order to test the reliability of the methodology. At the same time, the new data will be used to train the model, increasing the discriminatory power in terms of accuracy, precision, sensitivity and specificity
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2022.
- Background: PubMed 32576912Carlomagno C, Banfi PI, Gualerzi A, Picciolini S, Volpato E, Meloni M, Lax A, Colombo E, Ticozzi N, Verde F, Silani V, Bedoni M. Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis. Sci Rep. 2020 Jun 23;10(1):10175. doi: 10.1038/s41598-020-67138-8.
- Background: PubMed 30286833Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. 2018 Oct;93(10):1488-1502. doi: 10.1016/j.mayocp.2018.05.026.
- Background: PubMed 32745966Nikolaou V, Massaro S, Fakhimi M, Stergioulas L, Price D. COPD phenotypes and machine learning cluster analysis: A systematic review and future research agenda. Respir Med. 2020 Sep;171:106093. doi: 10.1016/j.rmed.2020.106093. Epub 2020 Jul 28.
- Background: PubMed 22196477Miravitlles M, Calle M, Soler-Cataluna JJ. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch Bronconeumol. 2012 Mar;48(3):86-98. doi: 10.1016/j.arbres.2011.10.007. Epub 2011 Dec 22. English, Spanish.
- Laboratory of Nanomedicine and Clinical Biophotonics, IRCCS Fondazione Don Carlo Gnocchi ONLUS, Milano (Italy)Link provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Related trials for Chronic Obstructive Pulmonary Disease
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marzia Bedoni, PhD study chair
Fondazione Don Carlo Gnocchi ONLUS, Laboratory of Nanomedicine and Clinical Biophotonics
Paolo I Banfo, MD principal investigator
Fondazione Don Carlo Gnocchi ETS
5 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Obstructive Pulmonary Disease, run by Fondazione Don Carlo Gnocchi ETS at 5 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Italy, Germany, Latvia, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Paolo I Banfi, MD (0240308812 ext. +39, pabanfi@dongnocchi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identification of the salivary COPD Raman signature (time frame: Two years). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04628962, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2022.